4-乙基吲哚 | 344748-71-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 4-乙基吲哚
• 英文名称: 4-ethyl-1H-indole
• 英文别名: 1H-Indole, 4-ethyl-
• CAS: 344748-71-6
• 化学式: C₁₀H₁₁N
• mdl: MFCD11110385
• 分子量: 145.204
• InChiKey: DYRCVOZYYPHAKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  15.8
• 氢给体数：
  1
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  4-乙基吲哚 在 N,N-二甲基丙烯基脲 、 氢氧化钾 、 三氯化铝 、 sodium bromide 作用下， 反应 11.0h， 生成 4-ethyl-N,N-dimethyl-3-[4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]benzoyl]indole-1-carboxamide
  参考文献：
  名称：

  Discovery and Evaluation of a Series of 3-Acylindole Imidazopyridine Platelet-Activating Factor Antagonists

  摘要：

  Studies conducted with the goal of discovering a second-generation platelet-activating factor (PAF) antagonist have identified a novel class of potent and orally active antagonists which have high aqueous solubility and long duration of action in animal models. The compounds arose from the combination of the lipophilic indole portion of Abbott's first-generation PAF antagonist ABT-299 (2) with the methylimidazopyridine heterocycle moiety of British Biotechnology's BB-882 (1) and possess the positive attributes of both of these clinical candidates. Structure-activity relationship (SAR) studies indicated that modification of the indole and benzoyl spacer of lead compound 7b gave analogues that were more potent, longer-lived, and bioavailable and resulted in the identification of 1-(N,N-dimethylcarbamoyl)-4-ethynyl-3-(3-fluoro-4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl] benzoyl}indole hydrochloride (ABT-491, 22m.HCl) which has been evaluated extensively and is currently in clinical development.

  DOI：

  10.1021/jm970389+
• 作为产物：
  描述：

  乙二醇 、 3-乙基苯胺 在 silica gel 、 zirconium(IV) oxide 作用下， 以19.9%的产率得到6-乙基吲哚
  参考文献：
  名称：

  Reaction pathway in the vapour-phase synthesis of indole and alkylindoles

  摘要：

  The vapour-phase synthesis of indole and its derivatives from aniline or alkylanilines and ethylene glycol or other diols was investigated with the use of a novel ZrO2/SiO2 (5:95 w/w) catalyst to check the applicability of this synthesis to a wide number of alkylindoles. During feeding with alkylaniline, the above catalyst showed catalytic results better than those reported in the literature, and a very good regenerability. In particular, with ethylene glycol, the best yields in the corresponding indoles were obtained when a C-2-C-3 alkyl chain was located in the ortho position to the amino group. The differences in reactivity between aniline and alkylaniline were significantly reduced when the length of the diol chain was increased and eliminated with 2,3-butanediol. On the basis of the above data and those collected sharing the synthesis in single steps, a possible overall reaction pathway was proposed to design a better tailor-made catalyst. It was also indicated that the formation of heavy compounds, which are able to deactivate the catalyst, were not derived from the reagents or the following reactions on the indole formed, but might be mainly attributed to the polycondensation of an aldehyde intermediate. (c) 2005 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.jcat.2005.02.014

文献信息

• Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor
  申请人：Asselin Magda

  公开号：US20070027160A1

  公开（公告）日：2007-02-01

  The present invention relates to novel piperazine-piperidine compounds. The compounds are useful as 5-HT 1A binding agents, particularly as 5-HT 1A receptor antagonists and agonists. These compounds are useful in treating central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction.

  本发明涉及新型哌嗪-哌啶化合物。这些化合物可用作5-HT1A结合剂，特别是作为5-HT1A受体拮抗剂和激动剂。这些化合物在治疗中枢神经系统疾病方面很有用，如认知障碍、焦虑症、抑郁症和性功能障碍。
• Substituted Quinazoline and Pyridopyrimidine Derivatives Useful as Anticancer Agents
  申请人：PFIZER INC.

  公开号：US20190233440A1

  公开（公告）日：2019-08-01

  Compounds of the general formula: processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

  具有通用公式： 这些化合物的制备方法，包含这些化合物的组合物，以及这些化合物的用途。
• [EN] INHIBITORS OF PI3 KINASE<br/>[FR] INHIBITEURS DE LA PI3 KINASE
  申请人：CT NAC INVESTIGACIONES ONCOLOGICAS CNIO

  公开号：WO2011089400A1

  公开（公告）日：2011-07-28

  There is provided compounds of formula (I), wherein A1, A4, A4a, A5, B1, B1a, B2, B2a, B3, B3a, B4, B4a and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

  提供了式（I）的化合物，其中A1、A4、A4a、A5、B1、B1a、B2、B2a、B3、B3a、B4、B4a和R3的含义如描述中所给，并且其药学上可接受的酯、酰胺、溶剂合物或盐，这些化合物在治疗需要或期望抑制蛋白激酶或脂质激酶（例如PI3-K和/或mTOR）的疾病中非常有用，特别是在癌症或增生性疾病的治疗中。
• [EN] MODIFIED PROTEINS AND PROTEIN DEGRADERS<br/>[FR] PROTÉINES MODIFIÉES ET AGENTS DE DÉGRADATION DE PROTÉINES
  申请人：CULLGEN SHANGHAI INC

  公开号：WO2021239117A1

  公开（公告）日：2021-12-02

  Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.

  本文提供了结合或降解靶蛋白的化合物、药物组合物和方法。本文还提供了具有DNA损伤结合蛋白1（DDB1）结合基团的化合物。其中一些实施例包括连接物。其中一些实施例包括靶蛋白结合基团。本文还提供了配体-DDB1复合物。本文还提供了体内修饰的DDB1蛋白。
• MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
  申请人：Binch Hayley

  公开号：US20100168094A1

  公开（公告）日：2010-07-01

  The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using such CFTR modulators.

  本发明涉及调节ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节蛋白，以及相关的组合物和方法。本发明还涉及利用这些CFTR调节剂治疗疾病的方法。